{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:41:55Z","timestamp":1793580115615,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Inhibiting coagulation factor XI (FXI) activity has emerged as a promising strategy to prevent intravascular thrombosis. Here, we describe the first-in-human trial with an N-acetylgalactosamine\u2013conjugated small interfering RNA (siRNA), RBD4059, targeting FXI. In this phase 1 single ascending dose study (NCT05653037), healthy volunteers were randomized to receive either active drug or placebo (6 + 2), administered subcutaneously, in 4 consecutive dose cohorts ranging from 50 mg to 600 mg. The primary end point was safety and tolerability up to day 169 after dose. Secondary end points included pharmacokinetic and pharmacodynamic (PD) parameters. Single ascending doses of RBD4059 were well tolerated, and no apparent safety concerns were identified. RBD4059 was associated with a dose-dependent and durable suppression of FXI activity up to &amp;gt;90%. Modeling of the available PD data supports clinical dosing schemes of 3 to 6 months to achieve a robust antithrombotic effect. Altogether, these observations support further clinical development of RBD4059 to provide an siRNA-based therapeutic option targeting FXI for patients inadequately treated with or contraindicated for current available thrombosis prophylaxis. This trial was registered at www.clinicaltrials.gov as #NCT05653037.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018348","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:18:17Z","timestamp":1767989897000},"page":"2541-2548","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran)"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8838-3463","authenticated-orcid":false,"given":"Anders","family":"Gabrielsen","sequence":"first","affiliation":[{"name":"1Ribocure Pharmaceuticals AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3712-0255","authenticated-orcid":false,"given":"Sebastian","family":"Ueckert","sequence":"additional","affiliation":[{"name":"1Ribocure Pharmaceuticals AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Nilsson","sequence":"additional","affiliation":[{"name":"1Ribocure Pharmaceuticals AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Charlotte","family":"Egnell","sequence":"additional","affiliation":[{"name":"1Ribocure Pharmaceuticals AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"2Suzhou Ribo Life Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[{"name":"1Ribocure Pharmaceuticals AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Svedlund","sequence":"additional","affiliation":[{"name":"1Ribocure Pharmaceuticals AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Friend","sequence":"additional","affiliation":[{"name":"3Nucleus Network Limited, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Suzhou Ribo Life Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicai","family":"Liang","sequence":"additional","affiliation":[{"name":"2Suzhou Ribo Life Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[{"name":"2Suzhou Ribo Life Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ming","family":"Gan","sequence":"additional","affiliation":[{"name":"1Ribocure Pharmaceuticals AB, Gothenburg, Sweden"},{"name":"2Suzhou Ribo Life Science, Beijing, China"},{"name":"4Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"8","key":"2026041411211229300_bib1","doi-asserted-by":"crossref","first-page":"E347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"issue":"36","key":"2026041411211229300_bib2","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"4","key":"2026041411211229300_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"2026041411211229300_bib4","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"2026041411211229300_bib5","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.3390\/jcm11216314","article-title":"Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders","volume":"11","author":"Campello","year":"2022","journal-title":"J Clin Med"},{"key":"2026041411211229300_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2023.08.001","article-title":"A new strategy for anticoagulation: the factor XI inhibitors","volume":"116","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"11","key":"2026041411211229300_bib7","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"Georgi","year":"2019","journal-title":"Stroke"},{"issue":"10","key":"2026041411211229300_bib8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"2026041411211229300_bib9","doi-asserted-by":"crossref","first-page":"9761","DOI":"10.1038\/s41598-022-13174-5","article-title":"Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis","volume":"12","author":"Pallares","year":"2022","journal-title":"Sci Rep"},{"issue":"15","key":"2026041411211229300_bib10","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.3390\/jcm12154890","article-title":"Persistently high levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"12","author":"Spiezia","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"2026041411211229300_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12933-023-01905-5","article-title":"Elevated plasma factor XI predicts cardiovascular events in patients with type 2 diabetes: a long-term observational study","volume":"22","author":"Paszek","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026041411211229300_bib12","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.tru.2024.100171","article-title":"The current landscape of factor XI inhibitors","volume":"15","author":"Engelen","year":"2024","journal-title":"Thromb Update"},{"issue":"3","key":"2026041411211229300_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2026041411211229300_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"6","key":"2026041411211229300_bib15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jacbts.2024.12.005","article-title":"Inhibition of factor XI using RBD4059: a novel GalNAc-siRNA with potent and durable antithrombotic effects","volume":"10","author":"Liang","year":"2025","journal-title":"JACC Basic Transl Sci"},{"issue":"5","key":"2026041411211229300_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"issue":"5","key":"2026041411211229300_bib17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","article-title":"Posttranscriptional regulation of the heterochronic gene lin-14 by W-4 mediates temporal pattern formation in C. elegans","volume":"75","author":"Wightman","year":"1993","journal-title":"Cell"},{"issue":"6669","key":"2026041411211229300_bib18","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"1","key":"2026041411211229300_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2026041411211229300_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/dmd.122.001107","article-title":"Clinical pharmacology of RNA interference\u2013based therapeutics: a summary based on food and drug administration\u2013approved small interfering RNAs","volume":"51","author":"Jing","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2026041411211229300_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/hae.12678","article-title":"Factor XI-related thrombosis and the role of concentrate treatment in factor XI deficiency","volume":"21","author":"Pike","year":"2015","journal-title":"Haemophilia"},{"issue":"3","key":"2026041411211229300_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/hae.12846","article-title":"In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiency","volume":"22","author":"Pike","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"2026041411211229300_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2026041411211229300_bib24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/eurheartj\/ehad123","article-title":"Reversal agents for current and forthcoming direct oral anticoagulants","volume":"44","author":"van Es","year":"2023","journal-title":"Eur Heart J"},{"issue":"20","key":"2026041411211229300_bib25","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/bloodadvances.2021005695","article-title":"Anticoagulant therapy in patients with congenital FXI deficiency","volume":"5","author":"Bravo-P\u00e9rez","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2541\/2513541\/blooda_adv-2025-018348-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2541\/2513541\/blooda_adv-2025-018348-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:21:22Z","timestamp":1776180082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2541\/565939\/RNA-interference-therapy-targeting-coagulation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018348","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,4,14]]}}}